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Abstract: Advances in extracorporeal membrane oxygenation (ECMO) technology are associated
with expanded indications, increased utilization and improved outcome. There is growing interest in
developing ECMO prognostication scores to aid in bedside decision making. To date, the majority
of available scores have been limited to mostly registry-based data and with mortality as the main
outcome of interest. There continues to be a gap in clinically applicable decision support tools to aid
in the timing of ECMO cannulation to improve patients’ long-term outcomes. We present a brief
review of the commonly available adult and pediatric ECMO prognostication tools, their limitations,
and future directions.
Keywords: ECMO; predictive scores; decision making
1. Introduction
Extracorporeal Membrane Oxygenation (ECMO) has seen its use exponentially in-
crease over the last two decades [1]. New compact devices, improvements in anti-coagulation
strategies and monitoring, and improvements in cannulation techniques have continued to
fuel the growth within the field, and more centers are now offering ECMO support [1].
As the technology has advanced, the field has seen the criteria for ECMO deployment
continue to expand, with progressively more centers pushing the boundaries and offering
ECMO for previously contraindicated disease processes and even in out-of-hospital settings.
ECMO mortality has slowly improved with recent trials demonstrating mortality in the
30–50% range, compared to over 40–70% in similar patients not receiving ECMO [2–5].
Despite these advances, the fundamental question of prognostication persists—who is
a good candidate for ECMO support?
This question has never been more pressing than during the recent COVID-19 pan-
demic. As resources are stretched thin, offering resource-intensive therapies approaches a
zero-sum situation in which difficult decisions must be made [6–10]. To date, the common
approaches have focused on identifying factors in either patient characteristics or complica-
tions, mostly prior to ECMO initiation, to develop prognostication scores. The developed
scores have mostly relied on registry-based data, especially for neonatal and pediatric
scores, and with mortality as the main outcome. We review the current prognostication
tools available to clinicians, their limitations, and the future directions of the field.
2. Current ECMO Prognostication Tools
Over the last two decades, several groups have put together prediction scores with
Area Under Receiver Operator Curve (AUC), ranging from 0.65 to 0.89 depending on the
group and indication evaluated.
2.1. Neonatal Respiratory Failure
Two current scores exist to predict ECMO outcomes in neonatal respiratory failure,
both derived from the Extracorporeal Life Support Organization (ELSO) registry. Both the
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Pittsburgh Index of Pre-ECMO Risk (PIPER) score [11] and Neonatal Risk Estimate Score
for Children Using Extracorporeal Respiratory Support (Neo-RESCUERS) [12] rely on a
combination of demographic, laboratory, and treatment data prior to ECMO cannulation
to predict survival.
The PIPER score demonstrated a 21% increase in mortality for each PIPER quartile.
The mortality data was also separated by presence or absence of CDH. They further
presented a combined model including ECMO duration and presence of complication
categories as independent variables and showed an improved AUC of 0.79.
Neo-RESCUERS analyzed neonates over overlapping periods of the registry to create
a development and validation dataset. They showed that patients in their lowest decile had
an observed mortality of 7% compared to a predicted mortality of 4.4%, while the highest
decile had an observed mortality of 65.6% compared to a predicted mortality of 67.5%.
Both scores present reasonable AUCs but neither have been externally validated
(Table 1). ECMO cannulation technique has also changed over time with more neonatal
veno-venous (VV) ECMO cannulations occurring than from the time this registry data
was collected.
Table 1. Prognostication scores for neonatal respiratory failure.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
PIPER [11]
Prior to ECMO Demographics
Apgar at 5 min <7




MAP <49 mm Hg
Laboratory Data
pO2 <34 mm Hg
Treatment Data




































AUC = area under receiver operator curve, ECMO = extracorporeal membrane oxygenation, # = number, CDH = congenital diaphragmatic
hernia, MAP = mean arterial pressure, PaO2 = partial pressure of oxygen, iNO = inhaled nitric oxide, VA = veno-arterial, ELSO =
Extracorporeal Life Support Organization.
2.2. Neonatal Congenital Diaphragmatic Hernia
There is one neonatal congenital diaphragmatic hernia (CDH) ECMO prediction tool
that is designed to be scored either with only variables from prior to cannulation or with the
addition of variables after cannulation [13]. The highest risk group within the pre-ECMO
score had a mortality of 75% compared to the mortality of the highest risk group as defined
by the on-ECMO score of 86%. As expected, the addition of on-ECMO variables results
in an improvement in the accuracy of the model (Table 2). These findings illustrated the
importance of ECMO complications when predicting mortality.
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Table 2. Prognostication scores for neonatal congenital diaphragmatic hernia.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
CDH
Pre-ECMO [13]
Prior to ECMO Demographics
Prior diaphragmatic hernia repair






















Prior to ECMO + On-ECMO
Treatment Data




dialysis, tamponade, CPR, sepsis)
2018 0.73 (0.71–0.76) No
AUC = area under receiver operator curve, ECMO = extracorporeal membrane oxygenation, # = number, CDH = congenital diaphragmatic
hernia, CPR = cardiopulmonary resuscitation, ELSO = Extracorporeal Life Support Organization.
2.3. Pediatric Respiratory Failure
Two scores exist for pediatric respiratory failure (Table 3): the Pediatric Risk Estimation
Score for Children Using Extracorporeal Respiratory Support (PED-Rescuers) score [14]
and the newer Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation
Prediction (P-Prep) score [15]. Both scores were developed utilizing data from the ELSO
registry with an overlap in the data collection period but with a slight difference in the
patient cohort age group. The PED-Rescuers score was developed and then validated
against a dataset also from the ELSO registry, while the P-Prep score underwent external
validation against another large pediatric database, the Pediatric Health Information System
(PHIS). Both scores rely on pre-ECMO data regarding demographics including diagnosis,
as well as laboratory and treatment variables. Since they were published, the incidence
of pediatric respiratory ECMO has continued to increase, and the ELSO registry has
transitioned to ICD-10 coding from ICD-9, which may provide more granular diagnosis
data. Additionally, the ELSO registry underwent extensive revision and standardization of
all data fields in 2018 to provide a more standardized approach across centers and to allow
for more reliable multicenter data analysis [16].
Table 3. Prognostication scores for pediatric respiratory failure.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
PED-RESCUERS
[14]
Prior to ECMO Demographics
Comorbidities
















29 days to 18 years
# of Patients
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Table 3. Cont.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
P-PREP [15]
Prior to ECMO Demographics
Gender
Age >10 years



























AUC = area under receiver operator curve, ECMO = extracorporeal membrane oxygenation, # = number, PHIS = pediatric Health
Information System, MV = mechanical ventilation, CPR = cardiopulmonary resuscitation, ELSO = Extracorporeal Life Support Organization,
VV = veno-venous, VA = veno-arterial, HFOV = high frequency oscillatory ventilation, iNO = inhaled nitric oxide.
2.4. Adult Respiratory Failure
Several Adult Respiratory Failure scores exist (Table 4), with the earliest being EC-
MOnet developed on data from the 2009 H1N1 Pandemic [17]. This score was limited to a
single country cohort entered into an international research collaborative, ECMOnet [18].
They analyzed 60 patients, finding an overall survival rate of 68%. Predictors included
hospital length of stay prior to ECMO, bilirubin, creatinine, hematocrit, and mean arterial
pressure. These variables were split into categorical values and translated into scores. The
external test set revealed AUC of 0.69 with an accuracy of 62%, sensitivity of 51%, and
specificity of 62%.
Since that time, several other scores have been developed. Utilizing data from three
French intensive care units (ICU), the PRedicting dEath for SEvere ARDS on VV-ECMO
(PRESERVE) score was developed, including 140 patients with refractory acute respiratory
distress syndrome (ARDS) and eight pre-ECMO parameters as predictors [19]. Infectious
diseases were the leading cause of ARDS with 26% being infected with influenza H1N1.
They found that the pre ECMO P:F ratio was not associated with survival, and due to
trials around this time showing improved mortality with early prone positioning, the
authors forced it into their model and found it was independently associated with lower
mortality. In addition to aiming to identify factors associated with long-term mortality
for ICU survivors at 6-months post-discharge with 80% of survivors participating, they
looked at health-related quality of life (HRQOL) and reported emotional (34%), anxiety
(25%), depression or post-traumatic stress (PTSD) symptoms (16%). They further compared
HRQL outcomes in their population compared to controls, as well as other ECMO and
ARDS trials.
The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP)
score was developed with ELSO registry data and then externally validated on single center
data used to develop the PRESERVE score [20]. It was further validated in several other
independent studies [21,22]. Survival within the registry data was 57%; several diagnosis
groups were associated with mortality, and acute non-pulmonary infections and central
nervous system dysfunction were also significant predictors. Included variables were then
scored, and the final score was split into five risk classes with risk class I demonstrating 92%
survival vs risk class V with 18% survival. Prone positioning was not reported within the
registry and thus was not a predictor. The RESP score also performed better in the external
database compared to classical ICU severity scores such as simplified acute physiology
score II (SAPS II) and sequential organ failure assessment (SOFA).
Both RESP and PRESERVE scores have also been compared in separate independent
databases, where they were found to have similar accuracy in predicting both in-hospital
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and 6-months survival [23,24]. Of note—four variables overlap between the scores includ-
ing age, immunocompromised status, mechanical ventilation time prior to ECMO, and
peak inspiratory pressure (PIP) or plateau pressure.
Table 4. Prognostication scores for adult respiratory failure.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
ECMONet [17]
Prior to ECMO Demographics














60 H1N1 influenza A
patients with
respiratory distress
0.86 (0.75–0.96) Yes—0.69 (0.56–0.83)
PRESERVE [19]






MV > 6 days
No prone positioning prior to
ECMO
PEEP < 10 cm H2O









0.89 (0.83–0.94) Yes (0.68 (0.62–0.75)and 0.75 (0.57–0.92)) *
RESP [20]
Prior to ECMO Demographics
Age
Immunocompromised status
























0.74 (0.72–0.76) Yes (0.92 (0.89–0.97)and 0.81 (0.67–0.95)) *
Roch Score [25]












0.80 (0.71–0.89) Yes (0.56 (0.45–0.68))**
VV [26]












VV ECMO for ARDS
0.76 (0.67–0.85) No
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Table 4. Cont.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
PRESET [27]
Prior to ECMO Demographics
















0.85 (0.76–0.93) Yes (0.70 (0.56–0.84))
AUC = area under receiver operator curve, ECMO = extracorporeal membrane oxygenation, # = number, ELSO = Extracorporeal Life
Support Organization, VV = veno-venous, VA = veno-arterial, CNS = central nervous system, iNO = inhaled nitric oxide, BMI = body
mass index, SOFA = Sequential Organ Failure Assessment, ICU = intensive care unit, ARDS = acute respiratory distress syndrome. * These
findings were validated externally in separate databases not included in the original study ** Validated in the same database as used for
PRESET Score.
The Roch score focused on identifying factors associated with mortality in patients re-
ferred to a single center for acute respiratory distress syndrome (ARDS) and then requiring
ECMO support [25]. They looked at 85 consecutive ARDS patients equipped with ECMO
by a mobile team, with the median time to cannulation 3 h after contact from the referring
center. The variables were assigned scores with the 0–2 score group having 40% mortality
and the 3–4 score having 93% mortality. The strength of the Roch score is its development
in a referral center setting.
While several other scores have been developed on either multi or single center
data and then been externally validated, in general they have achieved good accuracy
in predicting mortality with only limited variables. These include the Veno-venous (VV)
ECMO mortality score [26] and PREdiction of Survival on ECMO Therapy-Score (PRESET)
score [27]. The PRESET score was derived with 108 ARDS patients on VV-ECMO who were
retrospectively analyzed with the EMCOnet, RESP, PRESERVE and Roch score. Within
their dataset, only the ECMOnet and RESP score accurately determined survival, and
subsequently the PRESET score was created including extrapulmonary predictors such
as mean arterial pressure, lactate, pH, platelets, and hospital days pre-ECMO. The scores
were then split into three risk classes with risk class I having 26% mortality vs risk class III
with 93% mortality.
A recent single center external validation also looked at these scores (PRESERVE,
RESP, VV-ECMO mortality, and SOFA scores). The authors found slightly lower AUCs
than previously reported between 0.64–0.73 [21].
2.5. Adult Cardiac Failure
Three large adult prognostic scores for survival for cardiac veno-arterial (VA) ECMO
exist (Table 5). The SAVE score is based off the ELSO registry data [28]. It was designed to
predict survival from refractory cardiogenic shock. Registry data showed a 42% survival,
the score was then validated on 161 Australian patients. The score was then split into risk
classes from I to IV, with survival in class I at 75% vs. class IV at 18%. They further compared
these risk categories across the most prevalent diagnosis groups, with myocarditis and
heart and lung transplants having the highest survival. The external validation AUC was
quite high (0.90), but it was done on a single highly protocolized center with higher survival
and difference in diagnosis distribution. This center also participated in the ELSO registry
so there may be some overlap between these cohorts.
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Table 5. Prognostication scores for adult cardiac failure.
Score Variables Year Patient Cohort AUC (95% CI) External Validation
SAVE [28]








DBP before ECMO >40 mmHg
PP before ECMO <20 mmHg
Laboratory Data
HCO3 < 15 mmol/L
Treatment Data
Duration of intubation prior to
initiation of ECMO






















































(6 h) & 0.74
(0.65–0.82) (12 h)
AUC = area under receiver operator curve, ECMO = extracorporeal membrane oxygenation, # = number, ELSO = Extracorporeal Life
Support Organization, VA = veno-arterial, DBP = diastolic blood pressure, PP = pulse pressure, AMI = acute myocardial infarction. * These
findings were validated externally in separate databases not included in the original study ** Validated in the same database as used for
PREDICT VA-ECMO Score.
The prEdictioN of Cardiogenic shock OUtcome foR AMI (Acute Myocardial Infarction)
patients salvaGed by VA-ECMO (ENCOURAGE) score was based off multicenter data of
138 patients and also followed up on HRQOL data [29]. It was developed over 138 patients
from two centers and was unique in that it was the first specific risk score for AMI-
cardiogenic shock. They demonstrated 47% survival and had seven pre-ECMO predictors.
Their HRQOL data was compared among score classes with 6-month survival ranging
from 7 to 80%. They also reported anxiety (34%), depression (20%), and PTSD (5%) among
their survivors.
Conversely, the Predict VA-ECMO score is based off variables for patients already on
ECMO, relying on very few variables at different time intervals with good accuracy [30].
They were able to develop a dynamic score using only three points of care biomarkers,
and it outperformed the SAVE score within their database. A significant strength was
the evaluation of extracorporeal cardiopulmonary resuscitation (eCPR) patients as well as
cardiogenic shock patients.
3. Limitations in Current Prognostic Scores
The majority of prediction models aim to predict the same outcome—mortality. Aside
from CDH on-ECMO score and Predict VA-ECMO, all scores take input variables from
pre-ECMO cannulation to help predict mortality. As one would expect looking at the
variables of interest, a patient’s severity of illness and degree of end organ dysfunction
prior to ECMO initiation often plays a large role in their predicted mortality. Unfortunately,
there are limited trials to help establish when a patient would best benefit from cannulation,
as both too early and too late cannulation could be associated with adverse outcomes. In
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other words, the current models do not provide clinicians with decision support tools for
timely institution of ECMO support, before end organ deterioration develops that has been
shown to correlate with worse in-hospital and long-term mortality.
While several adult scores have been designed without registry data or are externally
validated, many pediatric scores are not externally validated. External validation is often
crucial to ensure a prediction score is applicable to varying patient cohorts with differ-
ences in demographics, therapeutics, and even diagnoses. Recent studies have shown
even externally validated adult scores performed similarly and with lower accuracy than
initially reported [23,24]. Recent literature has been published on how some of these scores
performed retrospectively during the COVID-19 pandemic [2]. Recent evidence from the
COVID-19 pandemic has also shown that the timing of ECMO initiation influences patient
outcomes [32].
A common factor is that a large portion of predictive variables only point to existing
end organ dysfunction prior to cannulation but provide scant evidence on modifiable risk
factors either in the pre or on ECMO phases. They also mostly predict only short-term
mortality, but provide limited information on long-term neurologic or functional outcomes.
4. Future Directions
As described in a recent joint paper regarding the development and reporting of
prediction models from respiratory, sleep, and critical care journals—a significant limita-
tion of prediction models is the inclusion of casual relationships between variables [33].
Variables such as pre-ECMO cardiac arrest or SOFA score are independently related to
mortality—with or without ECMO cannulation. Furthermore, the joint paper discusses the
limitations of categorizing continuous variables and the subsequent loss of information.
For example, a model that treats hypotension, mean arterial pressure (MAP) <60 mmHg,
as a binary variable, may treat MAPs of 39 and 59 mmHg the same, as well as the folly of
relying only on AUC curves without considering the importance of precision and recall,
especially when datasets are unbalanced [34]. As survival improves overall, especially for
conditions such as CDH, it is increasingly likely that there will be significantly unbalanced
classes (higher survival). Both these limitations impact the vast majority of current ECMO
prediction scores.
Further, while current prediction scores can inform clinical decisions regarding pop-
ulation level statistics of who will survive ECMO, they offer little in the way of input
on how to improve these outcomes. Most rely on demographics and pre-cannulation
markers of severity of illness or pre-ECMO cardiac arrest [35,36]. Research has also focused
on factors that relate to continued multiorgan failure such as need for renal replacement
therapy [23,37], continued need for vasoactive support, or markers of hemolysis or dissem-
inated intravascular coagulation [38,39].
Little has been offered in terms of ECMO predictive scores that alert clinicians of
actionable variables that may impact outcomes. Recent adult literature has shown in a
large ELSO database that a significant relative decrease in PaCO2 in respiratory ECMO
patients was associated with poor neurologic outcomes [40]. Pediatric data has shown the
importance of PaCO2 and its interaction with blood pressure on cerebral autoregulation in
a single center [41]. Studies in pediatric patients have also shown the impact of hyperoxia
on neurologic outcomes [42,43]. Other literature has focused on the impact of cannulation
modality and mortality [44,45].
Factors such as relative changes in PaCO2, MAP, cannulation Site, and degree of
hyperoxia are often modifiable by experienced clinical staff. Predictive scores with a focus
on a change in variables over time and their impact on mortality are sorely needed to aid
not only in the decision to place a patient on ECMO, but to predict and impact outcomes
following cannulation.
These challenges also remain ever present during the current COVID-19 pandemic,
with the RESP & PRESERVE score having AUCs of 0.60 and 0.55 in a multicenter COVID-19
database [2]. The complexity of the COVID-19 patients in that they may require longer
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durations of mechanical ventilation, may have more significant ARDS and overall increased
treatment complexity is not well reflected in either of these scores. We propose new COVID-
19-specific scores should be developed that can include these further nuances. We further
propose these prediction scores should be under continuous development and revision,
which will improve their ability to serve as true clinical decision support tools.
5. Changing the Outcome
Deployment of ECMO has become more widespread with nearly a 10-fold increase
over the last two decades. Recent trials have also documented the improvement in mortality
outcomes provided by ECMO support. As with other interventions that have become more
widespread in critical care, the focus shifts from a binary outcome of mortality to more
nuanced patient-centered outcomes.
Neurologic injury is one of the most common complications of ECMO, with neurologic
complications such as intracranial hemorrhage associated with upwards of 40% of deaths.
Children are similarly affected with survival falling to 36–38% following acute neurologic
injury. In children in particular, long term follow up has also demonstrated that survivors
often have significant impairment—12% report severe motor impairment, 10–50% with
cognitive delays, 16–46% with behavioral abnormalities, and 31–53% of survivors having
quality of life scores at least one standard deviation below the mean. Likewise, a standard-
ized 1-year follow up clinic after respiratory ECMO demonstrated neurodevelopmental
problems in 30% of the 98 patients [46]. Prior papers have focused on the role of cannulation
sites, PaCO2 change, and hyperoxia amongst others, for their roles in neurologic injury.
Unfortunately, neurologic outcome has not been the focus of prediction models, likely due
to heterogenous conditions of patients pre-ECMO, the role of their pre-ECMO illness, and
difficulty in collecting and analyzing long term data. Despite these challenges, the next
generation of prediction models may benefit from focus on neurologic outcomes rather
than survival and ICU discharge, as previously mentioned.
6. Conclusions
We present a review of current ECMO prediction models in neonatal, pediatric, and
adult ECMO patients developed over the last decade, as well as a challenge for the next gen-
eration of models to focus on accuracy as well as precision, clinically modifiable outcomes,
and outcomes aside from mortality such as long-term neurologic and functional status.
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